The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kubyshkin V.A.

FGBU "Institut khirurgii im. A.V. Vishnevskogo" Minzdrava Rossii, Moskva

Kochatkov A.V.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Ingibitors of proton pump in the treatment of zollinger-Ellison syndrom

Authors:

Kubyshkin V.A., Kochatkov A.V.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2012;(12): 67‑71

Read: 1997 times

Download PDF (RU)
Contact the author
Table of contents

INGIBITORS OF PROTON PUMP IN THE TREATMENT OF ZOLLINGER-ELLISON SYNDROM
INGIBITORS OF PROTON PUMP IN THE TREATMENT OF ZOLLINGER-ELLISON SYNDROM

To cite this article:

Kubyshkin VA, Kochatkov AV. Ingibitors of proton pump in the treatment of zollinger-Ellison syndrom. Pirogov Russian Journal of Surgery. 2012;(12):67‑71. (In Russ.)

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Functional dyspepsia: approaches to diagnosis and treatment in the context of Russian clinical practice. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):43-49
Abstract:

Keywords:

Zollinger-Ellison syndrom
controloc
ingibitors of proton pump

Authors:

Kubyshkin V.A.

FGBU "Institut khirurgii im. A.V. Vishnevskogo" Minzdrava Rossii, Moskva

Kochatkov A.V.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Close metadata

References:

  1. Akerstrom G., Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007; 21: 1: 87-109.
  2. Akerstrom G., Hessman O., Skogseid B. Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. Langenbecks Arch Surg 2002; 386: 8: 558-569.
  3. Anlauf M., Garbrecht N., Henopp T., Schmitt A., Schlenger R., Raffel A., Krausch M., Gimm O., Eisenberger C.F., Knoefel W.T., Dralle H., Komminoth P., Heitz P.U., Perren A., Kloppel G. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol 2006; 14: 12: 34: 5440-5446.
  4. Avner D.L. Clinical experience with pantoprazole in gastroesophageal reflux disease. Clin Ther 2000; 22: 10: 1169-1185; discussion 1149-1150.
  5. Beck I.T., Champion M.C., Lemire S., Thomson A.B., Anvari M., Armstrong D., Bailey R.J., Barkun A.N., Boivin M., Bursey R.F., Chaun H., Chiba N., Cockeram A.W., Connon J.J., Da Costa L.R., Faloon T.R., Fedorak R.N., Gillies R.R., Goeree R., Hunt R.H., Inculet R.I., Klein A., Leddin D.J., Love J.R., Worobetz L.J. et al. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. Can J Gastroenterol 1997; 11: Suppl B: 7-20.
  6. WHO classification of tumours of the digestive system. World Health Organization classification of tumours. Bosman F.T., World Health Organization., International Agency for Research on Cancer. 4th izd. Lyon: International Agency for Research on Cancer, 2010; 3: World Health Organization classification of tumours 417.
  7. Chubenko S.S., Gaidukov V.O., Agibalov A.N., Onishenko A.V. Efficacy of controloc in the treatment of acid-dependent diseases. Lik Sprava 2003; 8: 103-104.
  8. Colin-Jones D.G. Acid-related disorders: what are they? Scand J Gastroenterol Suppl 1988; 155: 8-11.
  9. Corleto V.D., Annibale B., Gibril F., Angeletti S., Serrano J., Venzon D.J., Delle Fave G., Jensen R.T. Does the widespread use of proton pump inhibitors mask, complicate and/or delay the diagnosis of Zollinger-Ellison syndrome? Aliment Pharmacol Ther 2001; 15: 10: 1555-1561.
  10. Desir B., Poitras P. Oral pantoprazole for acid suppression in the treatment of patients with Zollinger-Ellison syndrome. Can J Gastroenterol 2001; 15: 12: 795-798.
  11. Fedorak R.N., Veldhuyzen van Zanten S., Bridges R. Canadian Digestive Health Foundation Public Impact Series: gastroesophageal reflux disease in Canada: incidence, prevalence, and direct and indirect economic impact. Can J Gastroenterol 2010; 24: 7: 431-434.
  12. Fishbeyn V.A., Norton J.A., Benya R.V., Pisegna J.R., Venzon D.J., Metz D.C., Jensen R.T. Assessment and prediction of long-term cure in patients with the Zollinger-Ellison syndrome: the best approach. Ann Intern Med 1993; 1: 119: 3: 199-206.
  13. Fitton A., Wiseman L. Pantoprazole. A review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51: 3: 460-482.
  14. Gawronska-Szklarz B., Adamiak-Giera U., Wyska E., Kurzawski M., Gornik W., Kaldonska M., Drozdzik M. CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers. Eur J Clin Pharmacol 2012; 68: 9: 1267-1274.
  15. Gibril F., Jensen R.T. Zollinger-Ellison syndrome revisited: diagnosis, biologic markers, associated inherited disorders, and acid hypersecretion. Curr Gastroenterol Rep 2004; 6: 6: 454-463.
  16. Gibril F., Jensen R.T. Advances in evaluation and management of gastrinoma in patients with Zollinger-Ellison syndrome. Curr Gastroenterol Rep 2005; 7: 2: 114-121.
  17. Hassall E. Decisions in diagnosing and managing chronic gastroesophageal reflux disease in children. J Pediatr 2005; 146: 3: Suppl: 3-12.
  18. Huber R., Kohl B., Sachs G., Senn-Bilfinger J., Simon W.A., Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995; 9: 4: 363-378.
  19. Jensen R.T., Cadiot G., Brandi M.L., de Herder W.W., Kaltsas G., Komminoth P., Scoazec J.Y., Salazar R., Sauvanet A., Kianmanesh R. Barcelona Consensus Conference p. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95: 2: 98-119.
  20. Jensen R.T., Niederle B., Mitry E., Ramage J.K., Steinmuller T., Lewington V., Scarpa A., Sundin A., Perren A., Gross D., O'Connor J.M., Pauwels S., Kloppel G., Frascati Consensus C. European Neuroendocrine Tumor S. Gastrinoma (duodenal and pancreatic). Neuroendocrinology 2006; 84: 3: 173-182.
  21. Kloppel G., Anlauf M. Gastrinoma - morphological aspects. Wien Klin Wochenschr 2007; 119: 19-20: 579-584.
  22. Lew E.A., Pisegna J.R., Starr J.A., Soffer E.F., Forsmark C., Modlin I.M., Walsh J.H., Beg M., Bochenek W., Metz D.C. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Gastroenterology 2000; 118: 4: 696-704.
  23. Liu C.P., Chen W.C., Lai K.H., Mar G.Y., Lin S.Y., Ger L.P., Hsu P.I. Formosa Acid-Related Disease Study G. Esomeprazole alone compared with esomeprazole plus aspirin for the treatment of aspirin-related peptic ulcers. Am J Gastroenterol 2012; 107: 7: 1022-1029.
  24. McKeage K., Blick S.K., Croxtall J.D., Lyseng-Williamson K.A., Keating G.M. Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults. Drugs 2008; 68: 11: 1571-1607.
  25. Metz D.C., Comer G.M., Soffer E., Forsmark C.E., Cryer B., Chey W., Pisegna J.R. Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions. Aliment Pharmacol Ther 2006; 1: 23: 3: 437-47.
  26. Metz D.C., Forsmark C., Lew E.A., Starr J.A., Soffer E.F., Bochenek W., Pisegna J.R. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. Am J Gastroenterol 2001; 96: 12: 3274-3280.
  27. Metz D.C., Soffer E., Forsmark C.E., Cryer B., Chey W., Bochenek W., Pisegna J.R. Maintenance oral pantoprazole therapy is effective for patients with Zollinger-Ellison syndrome and idiopathic hypersecretion. Am J Gastroenterol 2003; 98: 2: 301-307.
  28. Acid related diseases biology and treatment. Modlin I.M., Sachs G. 2nd izd. Philadelphia: Lippincott Williams & Wilkins 2004; XVII: 522.
  29. Norton J.A., Alexander H.R., Fraker D.L., Venzon D.J., Gibril F., Jensen R.T. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg 2001; 234: 4: 495-505; discussion 505-506.
  30. Norton J.A., Fraker D.L., Alexander H.R., Venzon D.J., Doppman J.L., Serrano J., Goebel S.U., Peghini P.L., Roy P.K., Gibril F., Jensen R.T. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med 1999; 26: 341: 9: 635-644.
  31. Norton J.A., Jensen R.T. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg 2004; 240: 5: 757-773.
  32. Pohle T., Domschke W. Results of short-and long-term medical treatment of gastroesophageal reflux disease (GERD). Langenbecks Arch Surg 2000; 385: 5: 317-323.
  33. Pue M.A., Laroche J., Meineke I., de Mey C. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 1993; 44: 6: 575-578.
  34. Ramdani A., Mignon M., Samoyeau R. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. Gastroenterol Clin Biol 2002; 26: 4: 355-359.
  35. Roy P.K., Venzon D.J., Feigenbaum K.M., Koviack P.D., Bashir S., Ojeaburu J.V., Gibril F., Jensen R.T. Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis--a prospective NIH study of 235 patients and a review of 984 cases in the literature. Medicine (Baltimore) 2001; 80: 3: 189-222.
  36. Roy P.K., Venzon D.J., Shojamanesh H., Abou-Saif A., Peghini P., Doppman J.L., Gibril F., Jensen R.T. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 2000; 79: 6: 379-411.
  37. Ruszniewski P., Amouyal P., Amouyal G., Grange J.D., Mignon M., Bouche O., Bernades P. Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome. Surgery 1995; 117: 6: 629-635.
  38. Sanaka M., Yamamoto T., Kuyama Y. Effects of proton pump inhibitors on gastric emptying: a systematic review. Dig Dis Sci 2010; 55: 9: 2431-2440.
  39. Schepp W., Rehner M., Witzel L. A review of treatment of duodenal and gastric ulcers-pantoprazole vs. omeprazole. Aliment Pharmacol Ther 1994; 8: Suppl 1: 53-57.
  40. Selby N.M., Kubba A.K., Hawkey C.J. Acid suppression in peptic ulcer haemorrhage: a 'meta-analysis'. Aliment Pharmacol Ther 2000; 14: 9: 1119-1126.
  41. Sjodin I., Svedlund J., Dotevall G., Gillberg R. Symptom profiles in chronic peptic ulcer disease. A detailed study of abdominal and mental symptoms. Scand J Gastroenterol 1985; 20: 4: 419-427.
  42. Soll A.H., Fass R. Gastroesophageal reflux disease: presentation and assessment of a common, challenging disorder. Clin Cornerstone 2003; 5: 4: 2-14; discussion 14-17.
  43. Sugg S.L., Norton J.A., Fraker D.L., Metz D.C., Pisegna J.R., Fishbeyn V., Benya R.V., Shawker T.H., Doppman J.L., Jensen R.T. A prospective study of intraoperative methods to diagnose and resect duodenal gastrinomas. Ann Surg 1993; 218: 2: 138-144.
  44. Sugimoto M., Nishino M., Kodaira C., Yamade M., Ikuma M., Tanaka T., Sugimura H., Hishida A., Furuta T. Esophageal mucosal injury with low-dose aspirin and its prevention by rabeprazole. J Clin Pharmacol 2010; 50: 3: 320-330.
  45. Tack J., Fass R. Review article: approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder? Aliment Pharmacol Ther 2004; 19: Suppl 1: 28-34.
  46. Thjodleifsson B. Treatment of acid-related diseases in the elderly with emphasis on the use of proton pump inhibitors. Drugs Aging 2002; 19: 12: 911-927.
  47. Thompson N.W. Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med 1998; 243: 6: 495-500.
  48. Triponez F., Goudet P., Dosseh D., Cougard P., Bauters C., Murat A., Cadiot G., Niccoli-Sire P., Calender A., Proye C.A. French Endocrine Tumor Study G. Is surgery beneficial for MEN1 patients with small (
  49. Tytgat G.N. Review article: Practical management issues for the Helicobacter pylori-infected patient at risk of gastric cancer. Aliment Pharmacol Ther 1998; 12: Suppl 1: 123-128.
  50. Ward R.M., Kearns G.L., Tammara B., Bishop P., O'Gorman M.A., James L.P., Katz M.H., Maguire M.K., Rath N., Meng X., Comer G.M. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease. J Clin Pharmacol 2011; 51: 6: 876-887.
  51. Weber H.C., Venzon D.J., Lin J.T., Fishbein V.A., Orbuch M., Strader D.B., Gibril F., Metz D.C., Fraker D.L., Norton J.A. et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108: 6: 1637-1649.
  52. Yu F., Venzon D.J., Serrano J., Goebel S.U., Doppman J.L., Gibril F., Jensen R.T. Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 1999; 17: 2: 615-630.
  53. Zollinger R.M., Ellison E.C., Fabri P.J., Johnson J., Sparks J., Carey L.C. Primary peptic ulcerations of the jejunum associated with islet cell tumors. Twenty-five-year appraisal. Ann Surg 1980; 192: 3: 422-430.
  54. Zollinger R.M., Ellison E.H. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955; 142: 4: 709-723; discussion, 724-728.
  55. Bredikhina N.A., Kovanova L.A. Individual'nye varianty antisekretornogo effekta razlichnykh IPN pri kislotozavisimykh sostoyaniyakh. Prilozhenie 1. Eksperimental'naya i klinicheskaya gastroenterologiya 2007; 1: 33-34.
  56. Vasil'ev Yu.V. Ingibitory protonnogo nasosa. Lechashchii Vrach 2007; 1: 3-7.
  57. Ivashkin V.T. Shkola klinitsista. Yazvennaya bolezn' - istoriya meditsiny. Meditsinskii vestnik 2006; 19: 362: 9-10.
  58. Ivashkin V.T., Sheptulin A.A. Perspektivy primeneniya blokatorov protonnogo nasosa v gastroenterologii. Ros med zhur. Bolezni organov pishchevareniya 2001; 3: 1: 3-7.
  59. Khavkin A.I., Zhikhareva N.S. Medikamentoznaya terapiya yazvennoi bolezni u detei. Lechashchii vrach 2006; 1: 26-30.
  60. Yakovenko A.V., Grigor'ev P.Ya., Yakovenko E.P. Tsitoprotektory v terapii zabolevanii zheludka. Eksperim i klin gastroenterol 2006; 2: 1-4.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.